Synthetic teichoic acid conjugate vaccine against nosocomial Gram-positive bacteria

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Laverde, Diana ^a,b   Wobser, Dominique ^a   Romero Saavedra, Felipe ^a,b   Hogendorf, Wouter ^c   Van Der Marel, Gijsbert ^c   Berthold, Martin ^a   Kropec, Andrea ^a   Codee, Jeroen ^c   Huebner, Johannes ^a,d,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITÉ DE CAEN   (France)

^c LEIDEN UNIVERSITY   (Netherlands)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e German Center of Infection Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BOVINE SERUM ALBUMIN; IMMUNOGLOBULIN G ANTIBODY; LIPOTEICHOIC ACID CONJUGATE VACCINE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTISERUM; BACTERIUM ANTIBODY; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; OPSONIN; RECOMBINANT VACCINE; TEICHOIC ACID; VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; IMMUNOTHERAPY; MOUSE; NONHUMAN; OPSONIZATION; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; RAT; SEPSIS; STAPHYLOCOCCUS AUREUS; ANIMAL; CHEMISTRY; CROSS INFECTION; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; RABBIT;

POSIBACTERIA;

ANIMALS; ANTIBODIES, BACTERIAL; CROSS INFECTION; ENTEROCOCCUS FAECIUM; IMMUNE SERA; IMMUNIZATION, PASSIVE; LIPOPOLYSACCHARIDES; MICE; OPSONIN PROTEINS; RABBITS; RATS; STAPHYLOCOCCUS AUREUS; TEICHOIC ACIDS; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 84908191412     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110953     Document Type: Article

References (45)

1. Theilacker C, Krueger WA, Kropec A, Huebner J. (2004) Rationale for the development of immunotherapy regimens against enterococcal infections. Vaccine. Vol. 22. pp. S31-S38. doi:10.1016/j.vaccine.2004.08.014.
2. Leendertse M, Willems RJL, Flierman R, de Vos AF, Bonten MJM, et al. (2010) The complement system facilitates clearance of Enterococcus faecium during murine peritonitis. J Infect Dis 201: 544-552. doi:10.1086/650341.
3. Weidenmaier C, Peschel A. (2008) Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. Nat Rev Microbiol 6: 276-287. doi:10.1038/nrmicro1861.
4. Huebner J, Quaas A, Krueger W.A., Goldmann DA, Pier G.B. (2000) Prophylactic and Therapeutic Efficacy of Antibodies to a Capsular Polysaccharide Shared among Vancomycin-Sensitive and - Resistant Enterococci. Infect Immun 68: 4631-4636. doi:10.1128/IAI.68.8.4631-4636.2000.
5. Neuhaus FC, Baddiley J. (2003) A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev 67: 686-723. doi:10.1128/MMBR.67.4.686.
6. Theilacker C, Kaczynski Z, Kropec A., Fabretti F, Sange T, et al (2006) Opsonic antibodies to Enterococcus faecalis strain 12030 are directed against lipoteichoic acid. Infect Immun 74: 5703-5712. doi:10.1128/IAI.00570-06.
7. Huebner J, Kropec-Huebner A, Van der Marel GA, Hogendorf WFJ, Codee JD (2012) European patent application (51). 1: 1-16. Available: http://www.google.com/patents/EP2500349A1?cl=en.
8. Theilacker C, Kropec A, Hammer F., Sava I, Wobser D, et al (2012) Protection against Staphylococcus aureus by antibody to the polyglycerolphosphate backbone of heterologous lipoteichoic acid. J Infect Dis 205: 1076-1085. doi:10.1093/infdis/jis022.
9. Morath S (2002) Synthetic Lipoteichoic Acid from Staphylococcus aureus Is a Potent Stimulus of Cytokine Release. J Exp Med 195: 1635-1640. doi:10.1084/jem.20020322.
10. Zähringer U., Lindner B, Inamura S., Heine H, Alexander C. (2008) TLR2 - promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213: 205-224. doi:10.1016/j.imbio.2008.02.005.
11. Chen Q, Dintaman J, Lees A., Sen G, Schwartz D, et al (2013) Novel synthetic (poly)glycerolphosphate-based antistaphylococcal conjugate vaccine. Infect Immun 81: 2554-2561. doi:10.1128/IAI.00271-13.
12. Mond JJ, Lees A, Snapper C.M. (1995) T cell-independent antigens type 2. Annu Rev Immunol 13: 655-692. doi:10.1146/annurev.iy.13.040195.003255.
13. Finn A (2004) Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 70: 1-14. doi:10.1093/bmb/ldh021.
14. Phalipon A, Tanguy M, Grandjean C., Guerreiro C, Bélot F, et al. (2009) A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol 182: 2241-2247. doi:10.4049/jimmu-nol.0803141.
15. Chu K-C, Wu C-Y (2012) Carbohydrate-based synthetic vaccines: does the synthesis of longer chains of carbohydrates make this a step ever closer? Future Med Chem 4: 1767-1770. doi:10.4155/fmc.12.102.
16. Hogendorf WFJ, Meeuwenoord N, Overkleeft H.S., Filippov DV, Laverde D, et al. (2011) Automated solid phase synthesis of teichoic acids. Chem Commun (Camb) 47: 8961-8963. doi:10.1039/c1cc13132j.
17. Hogendorf WFJ, Bos LJ vd, Overkleeft HS, Codée JDC, Marel GA vd (2010) Synthesis of an α-kojibiosyl substituted glycerol teichoic acid hexamer. Bioorganic Med Chem 18: 3668-3678. doi:10.1016/j.bmc.2010.03.071.
18. Hogendorf WFJ, Lameijer LN, Beenakker TJM, Herman S, Filippov D.V., et al. (2012) Fluorous Linker Facilitated Synthesis of Teichoic Acid Fragments: 2010-2013. doi:10.1021/ol2033652.
19. Hogendorf WFJ, Kropec A, Filippov D V, Overkleeft HS, Huebner J, et al (2012) Light fluorous synthesis of glucosylated glycerol teichoic acids. Carbohydr Res 356: 142-151. doi:10.1016/j.carres.2012.02.023.
20. Verez-Bencomo V., Fernández-Santana V, Hardy E, Toledo ME, Rodríguez MC, et al. (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305: 522-525. doi:10.1126/science. 1095209.
21. Fernández-Santana V., González-Lio R, Sarracent-Pérez J, Verez-Bencomo V (1998) Conjugation of 5-azido-3-oxapentyl glycosides with thiolated proteins through the use of thiophilic derivatives. Glycoconj J 15: 549-553. doi:10.1023/A:1006903524007.
22. Huebner J, Wang Y, Krueger W.A., Madoff LC, Martirosian G, et al. (1999) Isolation and Chemical Characterization of a Capsular Polysaccharide Antigen Shared by Clinical Isolates of Enterococcus faecalis and Vancomycin-Resistant Enterococcus faecium. Infect Immun 67: 1213-1219.
23. Heikens E, Bonten MJM, Willems RJL (2007) Enterococcal surface protein Esp is important for biofilm formation of Enterococcus faecium E1162. J Bacteriol 189: 8233-8240. doi:10.1128/JB.01205-07.
24. Voyich JM, Otto M, Mathema B., Braughton KR, Whitney AR, et al. (2006) Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 194: 1761-1770. doi:10.1086/509506.
25. Van der Ley P, Heckels JE, Virji M, Hoogerhout P, Poolman JT (1991) Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun 59: 2963-2971.
26. Drijfhout JW, Bloemhoff W, Poolman J.T., Hoogerhout P. (1990) Solid-phase synthesis and applications of N-(S-acetylmercaptoacetyl) peptides. Anal Biochem 187: 349-354. doi:10.1056/NEJMra011223.
27. Chen Q, Cannons JL, Paton J.C., Akiba H., Schwartzberg PL, et al. (2008) A novel ICOS-independent, but CD28- and SAP-dependent, pathway of T cell-dependent, polysaccharide-specific humoral immunity in response to intact Streptococcus pneumoniae versus pneumococcal conjugate vaccine. J Immunol 181: 8258-8266. doi:10.4049/jimmunol.181.12.8258.
28. Kropec A, Sava IG, Vonend C, Sakinc T., Grohmann E, et al. (2011) Identification of SagA as a novel vaccine target for the prevention of Enterococcus faecium infections. Microbiology 157: 3429-3434. doi:10.1099/mic.0.053207-0.
29. Haller C, Berthold M, Wobser D., Kropec A, Lauriola M, et al (2014) Cell-Wall Glycolipid Mutations and Their Effects on Virulence of E. faecalis in a Rat Model of Infective Endocarditis. PLoS One 9: e91863. doi:10.1371/journal.-pone.0091863.
30. Mond JJ, Lees A, Snapper C.M. (1995) T CELL-INDEPENDENT. Annu Rev Immunol 13: 655-692.
31. Yokoyama Y, Harabuchi Y. (2002) Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otorhinolaryngol 63: 235-241. doi:10.1016/S0165-5876(02)00021-6.
32. Cox AD, St. Michael F, Aubry A, Cairns CM, Strong PCR, et al. (2013) Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection. Glycoconj J 30: 843-855. doi:10.1007/s10719-013-9489-3.
33. Goldenberg HB, McCool TL, Weiser J.N. (2004) Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis 190: 1254-1263. doi:10.1086/424517.
34. Oberli MA, Hecht M-L, Bindschädler P, Adibekian A., Adam T, et al. (2011) A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 18: 580-588. doi:10.1016/j.chem-biol.2011.03.009.
35. Martin CE, Broecker F, Eller S., Oberli MA, Anish C, et al. (2013) Glycan arrays containing synthetic Clostridium difficile lipoteichoic acid oligomers as tools toward a carbohydrate vaccine. Chem Commun (Camb) 49: 7159-7161. doi:10.1039/c3cc43545h.
36. Weisman LE, Fischer GW, Thackray H.M., Johnson KE, Schuman RF, et al. (2009) Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. Int Immunopharmacol 9: 639-644. doi:10.1016/j.intimp.2009.02.008.
37. Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M., Schneider JH, et al. (2009) Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neon. doi:10.1128/AAC.01565-08.
38. Weisman LE, Thackray HM, Steinhorn R.H., Walsh WF, Lassiter HA, et al. (2011) A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 128: 271-279. doi:10.1542/peds.2010-3081.
39. Percy MG, Gründling A (2014) Lipoteichoic Acid Synthesis and Function in Gram-Positive Bacteria. Annu Rev Microbiol. doi:10.1146/annurev-micro-091213-112949.
40. Hufnagel M, Kropec A, Theilacker C., Huebner J. (2005) Naturally acquired antibodies against four Enterococcus faecalis capsular polysaccharides in healthy human sera. Clin Diagn Lab Immunol 12: 930-934. doi:10.1128/CDLI.12.8.930-934.2005.
41. Kelly-Quintos C., Kropec A, Briggs S., Ordonez CL, Goldmann DA, et al. (2005) The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis 192: 2012-2019. doi:10.1086/497604.
42. Romero-Steiner S., Musher DM, Cetron M.S., Pais LB, Groover JE, et al. (1999) Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 29: 281-288. doi:10.1086/520200.
43. Theilacker C, Kaczyński Z, Kropec A., Sava I, Ye L, et al (2011) Serodiversity of opsonic antibodies against Enterococcus faecalis-glycans of the cell wall revisited. PLoS One 6: e17839. doi:10.1371/journal.pone.0017839.
44. Graveline R, Segura M, Radzioch D., Gottschalk M. (2007) TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. Int Immunol 19: 375-389. doi:10.1093/intimm/dxm003.
45. Riordan KO, Lee J.C. (2004) Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 17: 218-234. doi:10.1128/CMR.17.1.218.